RxDoctor Payments Data

Katelyn Szymkowski

Physician Assistant · Buffalo, NYNPI 1790456887

Payments from drug & device makers

$1,424in general payments, 2019–2025

Across 64 payments — averaging $22.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$189
  • Vanda Pharmaceuticals Inc.$143
  • Pacira Therapeutics, Inc.$120
  • Biohaven Pharmaceutical Holding Company Ltd.$118
  • Boston Scientific$112
  • Gilead$100
  • plus $642 from 25 others

What the payments were for

  • Food & beverage$1,424100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,424 in reported general payments places this provider in the 80th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$13,330
Medicare patients
77
Services billed
176

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide40$68,544
JardianceEmpagliflozin39$48,995
EliquisApixaban26$23,135
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$22,339
TrulicityDulaglutide16$15,903
MyrbetriqMirabegron21$11,275
Breo ElliptaFluticasone/Vilanterol17$6,637
SynthroidLevothyroxine Sodium26$2,118
Levothyroxine Sodium141$2,063
Albuterol Sulfate HfaAlbuterol Sulfate61$1,961
Rosuvastatin Calcium118$1,656
Duloxetine Hcl48$1,271
Amlodipine Besylate136$1,264
Atorvastatin Calcium68$1,254
Metoprolol Succinate53$1,133

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$61$68,54440 claims
GSKTrelegy Ellipta, Breo Ellipta$18$28,97638 claims
PfizerEliquis$45$23,13526 claims
Lilly USA, LLCTrulicity$23$15,90316 claims
AbbVieSynthroid$189$2,11826 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$16$2,063141 claims
Almatica Pharma LLCSertraline Hcl$16$62644 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Buffalo

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →